IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0785805
(2001-02-16)
|
발명자
/ 주소 |
- Guittard, George V.
- Jao, Francisco
- Marks, Susan M.
- Kidney, David J.
- Gumucio, Fernando E.
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
17 인용 특허 :
30 |
초록
▼
A composition and a dosage form are disclosed comprising oxybutynin alone/or accompanied by another drug indicated for therapy. A method is disclosed for administering oxybutynin alone/or accompanied by a different drug or for administering oxybutynin and a different drug according to a therapeutic
A composition and a dosage form are disclosed comprising oxybutynin alone/or accompanied by another drug indicated for therapy. A method is disclosed for administering oxybutynin alone/or accompanied by a different drug or for administering oxybutynin and a different drug according to a therapeutic program for the management of incontinence alone, and for other therapy.
대표청구항
▼
1. A method for the management of incontinence in a patient, wherein the method comprises admitting orally into the patient a dosage form comprising 240 ng to 650 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, that releases the member at a c
1. A method for the management of incontinence in a patient, wherein the method comprises admitting orally into the patient a dosage form comprising 240 ng to 650 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, that releases the member at a controlled and sustained, substantially zero order rate of 0.05 mg per hour up to 0.850 mg per hour for about 24 hours.2. A pharmaceutical dosage form comprising 240 ng to 650 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salts, the dosage form being adapted to release the member at a controlled and sustained, substantially zero order release rate for about 24 hours.3. A dosage form comprising 5 mg to 250 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, wherein (i) said dosage form provides a maximum plasma oxybutynin concentration of about 0.28 ng/ml to about 0.45 ng/ml per mg of said member in said dosage form and (ii) wherein said dosage form delivers said member from said dosage form over a period of about 24 hours.4. The dosage form according to claim 3, wherein said salt is oxybutynin hydrochloride.5. The dosage form of claim 4, wherein said dosage form delivers at a substantially zero order rate of release.6. The dosage form according to claim 3, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.7. The dosage form according to claim 4, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.8. The dosage form of claim 3, wherein said dosage form delivers at a substantially zero order rate of release.9. The dosage form according to claim 3, wherein said dosage form is a tablet.10. The dosage form according to claim 4, wherein said dosage form is a tablet.11. The dosage form according to claim 6, wherein said dosage form is a tablet.12. The dosage form according to claim 7, wherein said dosage form is a tablet.13. A method for the management of incontinence in a patient comprising administration to a subject of a dosage form comprising 5 mg to 250 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, wherein (i) said dosage form provides a maximum plasma oxybutynin concentration of about 0.28 ng/ml to about 0.45 ng/ml per mg of said member in said dosage form and (ii) wherein said dosage form delivers said member from said dosage form over a period of about 24 hours.14. The method according to claim 13, wherein said salt is oxybutynin hydrochloride.15. The method according to claim 13, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.16. The dosage form of claim 13, wherein said dosage form delivers at a substantially zero order rate of release.17. The method according to claim 14, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.18. The dosage form of claim 17, wherein said dosage form delivers at a substantially zero order rate of release.19. The method according to claim 13, wherein said dosage form is a tablet.20. The method according to claim 14, wherein said dosage form is a tablet.21. The method according to claim 15, wherein said dosage form is a tablet.22. The method according to claim 17, wherein said dosage form is a tablet.23. The method according to any one of claim 13, 14, 15, 17, 19, 20, 21 or 22 wherein the incidence of side effects associated with oxybutynin treatment is reduced.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.